<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Serological evidence of <z:e sem="disease" ids="C0263591" disease_type="Disease or Syndrome" abbrv="">drug-induced lupus</z:e> (DIL) and <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) were detected in a paediatric patient with <z:e sem="disease" ids="C0015624" disease_type="Disease or Syndrome" abbrv="RFS|FRTS">nephropathic cystinosis</z:e> during work-up for live related renal transplantation </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="17141">Cysteamine</z:chebi> was considered the most likely cause </plain></SENT>
<SENT sid="2" pm="."><plain>Antinuclear (ANA) and antihistone antibodies disappeared after stopping <z:chebi fb="0" ids="17141">cysteamine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>ANA became positive after reintroduction of <z:chebi fb="0" ids="17141">cysteamine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>The patient's post-transplant course was complicated by severe <z:mp ids='MP_0005048'>thrombosis</z:mp>, with histological findings in her native nephrectomy consistent with APS </plain></SENT>
<SENT sid="5" pm="."><plain>This is the first reported case of DIL and APS secondary to <z:chebi fb="0" ids="17141">cysteamine</z:chebi> therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Clinicians should exclude autoimmune abnormalities in patients with <z:e sem="disease" ids="C0010690" disease_type="Disease or Syndrome" abbrv="">cystinosis</z:e>, especially if patients report non-specific, unusual or unexplained symptoms </plain></SENT>
</text></document>